Document Classification

Section Type: RESULTS

Text: In the ixekizumab every 2 weeks group, sPGA 0/1 was achieved by 292 (response rate 832 % ; [effect size 808 % (975 % CI 756-860) vs placebo ; 472 % (399-544) vs etanercept]) and 310 (805 % ; [738 % (677-799) vs placebo ; 389 % (317-461) vs etanercept]) patients ; in the ixekizumab every 4 weeks group by 253 (729 % ; [705 % (646-765) vs placebo ; 369 % (291-447) vs etanercept]) and 291 (754 % ; [687 % (623-750) vs placebo ; 338 % (263-413) vs etanercept]) patients ; in the placebo group by four (24 %) and 13 (67 %) patients ; and in the etanercept group by 129 (360 %) and 159 (416 %) patients (all p < 00001 vs placebo or etanercept).